AR and prostate carcinoma: Prostate cancer cell lines co‐treated with doxorubicin or other drugs only partially target the multidrug resistance proteins in tumours (Rybalchenko et al., 2001), where a synergistic effect in AR negative PC3 and DU145 cells was observed, but not in the AR positive prostate cancer cells.